• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Ocugen, Inc. - Common Stock (NQ:OCGN)

    1.672 +0.182 (+12.21%)
    Streaming Delayed Price Updated: 11:46 AM EST, Jan 22, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Ocugen, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    12 13 Next >
    News headline image
    Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen CEO to Present at NobleCon21—Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity Conference
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen Provides Business Update with Third Quarter 2025 Financial Results
    Conference Call and Webcast Today at 8:30 a.m. ET 
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen to Present at Industry and Investor Conferences in October 2025
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen Provides Business Update with Second Quarter 2025 Financial Results
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results
    From Ocugen
    Via GlobeNewswire
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Carisma Therapeutics Inc. (Nasdaq - CARM), Guaranty Bancshares, Inc. (NYSE - GNTY), MRC Global Inc. (NYSE - MRC), Turnstone Biologics Corp. (Nasdaq - TSBX)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    News headline image
    Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen To Present at BIO International Convention 2025
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen Provides Business Update with First Quarter 2025 Financial Results
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen to Present at the 2025 Cell & Gene Meeting on the Med
    From Ocugen
    Via GlobeNewswire
    News headline image
    Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema
    From Ocugen
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    12 13 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.